Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroOne Medical Technologies Corporation filings document the public-company records of a Nasdaq-listed medical technology issuer developing thin-film electrode and ablation systems for neurological procedures. Current reports and proxy materials disclose operating results, regulatory and clinical update categories, capital-structure actions, governance matters and stockholder voting items.
The company’s SEC record includes Form 8-K disclosures for financial results, Nasdaq listing compliance, certificate amendments, reverse stock split actions, officer and compensation matters, and annual-meeting scheduling. Its definitive proxy statement covers director elections, auditor ratification, equity incentive plan amendments, stockholder proposals and other governance votes tied to NeuroOne’s common stock.
NeuroOne Medical Technologies Corporation filed a current report stating that on December 17, 2025 it issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, along with Item 2.02, is treated as furnished rather than filed under the Exchange Act, which affects how it is incorporated into other Securities Act and Exchange Act filings. The company’s common stock trades on the Nasdaq Stock Market under the symbol NMTC.
NeuroOne Medical Technologies Corporation reports its annual update as a neurotechnology company developing thin-film electrodes for brain disorders, chronic pain and drug delivery. It now has four FDA 510(k)-cleared products: Evo cortical and sEEG diagnostic electrodes, the OneRF brain ablation system and the OneRF TN ablation system, with global brain distribution rights for brain applications licensed exclusively to Zimmer. Pipeline programs target spinal cord stimulation, basivertebral nerve ablation and agent-delivering neural electrodes.
The company relies on long-term licenses from WARF and Mayo and an amended Zimmer agreement that added OneRF distribution for a $3 million upfront payment plus potential sales milestones. An April 2025 equity offering of 18.4 million shares at $0.50 generated approximately $8.2 million of net proceeds, yet cash and cash equivalents were about $6.6 million as of September 30, 2025 against an accumulated deficit of $78.6 million. Auditors and management highlight substantial doubt about its ability to continue as a going concern, and Nasdaq has granted only a limited extension to regain the $1.00 minimum bid price.
NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share. Nasdaq granted a 180-day extension through May 4, 2026.
The extension has no immediate effect on the company’s listing; NMTC’s common stock remains fully listed on the Nasdaq Capital Market. The company previously had until November 3, 2025 to cure the deficiency and has not yet regained compliance.
NeuroOne plans to continue monitoring the closing bid price and to seek compliance within the extension period. If compliance is not regained by the new deadline, Nasdaq may notify the company that its common stock is subject to delisting, and the company would have the right to appeal to a Nasdaq Hearing Panel.
NeuroOne Medical Technologies Corporation reported an annual total product revenue of approximately $9.1M and held approximately $6.6M in cash and cash equivalents as of September 30, 2025. These figures were disclosed in a press release furnished on October 6, 2025 and signed by CEO David Rosa. The filing is an 8-K reporting the material event and includes an interactive data file.
NEUROONE MEDICAL TECHNOLOGIES (NMTC) Chief Technology Officer Steve Mertens reported a sale of 906 shares of common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 161,329 shares, held directly. The Form 4 was signed by an authorized representative on 10/01/2025.
Insider sale reported: Mark Christianson, Business Development Director of NeuroOne Medical Technologies (NMTC), reported a disposition of 253 shares of the company's common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 230,985 shares in a direct capacity. The Form 4 was signed by Emily Johns by power of attorney on 10/01/2025. The filing indicates the report was made by one reporting person and lists Christianson\'s Eden Prairie, MN address.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) director and CEO David A. Rosa reported a small sale of 2,458 shares of common stock at $0.8886 per share on 09/30/2025, leaving beneficial ownership of 1,156,373 shares. The filing documents a routine insider disposition while the reporting person retains a substantial equity stake, and the transaction was disclosed under Section 16 rules.
NeuroOne Medical Technologies (NMTC) insider sale disclosed on Form 4. The reporting person, Mark Christianson, identified as a director and Business Development Director, sold 30,000 shares of common stock on 09/05/2025 at a weighted average price of $0.7401 per share, with individual sale prices ranging from $0.7400 to $0.7518. After the reported transactions, the filing shows 231,238 shares beneficially owned. The Form 4 was signed by a power of attorney on 09/09/2025. No derivative securities are reported on this form.
NeuroOne Medical Technologies (NMTC) filed a Form 144 disclosing a proposed sale of 30,000 common shares through Edward Jones with an aggregate market value of $24,210. The filing lists 49,817,835 shares outstanding and an approximate sale date of 08/20/2025. The shares were acquired on 07/01/2025 as an award from NeuroOne Medical Technologies; the record shows 622,000 shares were acquired on that date and payment/nature is indicated as awarded. The filer reports no securities sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer.
NeuroOne Medical Technologies Corporation reported that on August 18, 2025 it received U.S. Food and Drug Administration 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the device for procedures that create radiofrequency lesions to treat pain, and for lesioning nerve tissue in functional neurosurgical procedures. The authorization gives NeuroOne regulatory approval to commercialize this system in the United States for these specific neurosurgical applications.